<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8809320</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1600</journal-id>
<journal-id journal-id-type="nlm-ta">Neuron</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuron</journal-id>
<journal-title-group>
<journal-title>Neuron</journal-title>
</journal-title-group>
<issn pub-type="ppub">0896-6273</issn>
<issn pub-type="epub">1097-4199</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26889809</article-id>
<article-id pub-id-type="pmc">4759656</article-id>
<article-id pub-id-type="doi">10.1016/j.neuron.2016.01.040</article-id>
<article-id pub-id-type="manuscript">NIHMS754820</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>DREADDs for Neuroscientists</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Roth</surname>
<given-names>Bryan L.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Pharmacology, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC 27514, USA</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Correspondence: <email>bryan_roth@med.unc.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>29</day>
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<day>17</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>17</day>
<month>2</month>
<year>2017</year>
</pub-date>
<volume>89</volume>
<issue>4</issue>
<fpage>683</fpage>
<lpage>694</lpage>
<!--elocation-id from pubmed: 10.1016/j.neuron.2016.01.040-->
<abstract>
<p id="P1">To understand brain function, it is essential that we discover how cellular signaling specifies normal and pathological brain function. In this regard, chemogenetic technologies represent valuable platforms for manipulating neuronal and non-neuronal signal transduction in a cell-type-specific fashion in freely moving animals. Designer Receptors Exclusively Activated by Designer Drugs (DREADD)-based chemogenetic tools are now commonly used by neuroscientists to identify the circuitry and cellular signals that specify behavior, perceptions, emotions, innate drives, and motor functions in species ranging from flies to nonhuman primates. Here I provide a primer on DREADDs highlighting key technical and conceptual considerations and identify challenges for chemogenetics going forward.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>